Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) finished Friday with a subtraction of -$0.06 to close at $13.45, a downside of -0.44 percent. An average of 600,360 shares of common stock have been traded in the last five days. There was a gain of $0.55 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 634,205 shares traded, while the 50-day average volume stands at 1,267,038.
DAWN stock has increased by 12.74% in the last month. The company shares reached their 1-month lowest point of $11.44 on 07/20/23. With the stock rallying to its 52-week high on 01/09/23, shares of the company touched a low of $10.84 and a high of $28.35 in 52 weeks. It has reached a new high 2 times so far this year and lost -37.50% or -$8.07 in price. In spite of this, the price is down -52.56% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DAWN stock investors should be aware that Day One Biopharmaceuticals Inc. (DAWN) stock had its last reported insider trading activity 68 days ago on Jun 09. In this transaction, the insider spent $19,664. Chief Executive Officer, Bender Jeremy, disposed of 3,104 shares at a price of $13.12 on May 16. The insider now owns more than $40,732 worth of shares. Prior to that, COO, CFO and Secretary York Charles N II went on to Sale 955 shares at $13.12 each on May 16. An amount of $12,532 was transacted.
Valuation Metrics
Day One Biopharmaceuticals Inc. (DAWN) stock’s beta is -2.00. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.23.
Financial Health
The quick ratio of Day One Biopharmaceuticals Inc. for the three months ended June 29 was 14.10, and the current ratio was 14.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at -$4.75 million compared to revenue of $146.91 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Day One Biopharmaceuticals Inc.’s return on assets was -43.00%.
Earnings Surprise
For the three-month period that ended June 29, Day One Biopharmaceuticals Inc. had $253.67 million in cash. In the quarter under review, the net income was up than the previous quarter. The analyst consensus anticipated Day One Biopharmaceuticals Inc.’s latest quarter earnings to come in at -$0.61 per share, but it turned out to be -$0.61, a 0.00% surprise. For the quarter, EBITDA amounted to -$49.16 million. Shareholders own equity worth $86.97 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Day One Biopharmaceuticals Inc. (DAWN) price momentum. RSI 9-day as of the close on 11 August was 64.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 46.27%.
As of today, DAWN’s price is $13.10 +4.26% or $0.55 from its 5-day moving average. DAWN is currently trading +15.45% higher than its 20-day SMA and -26.70% lower than its 100-day SMA. However, the stock’s current price level is +1.13% above the SMA50 and -31.80% below the SMA200.
The stochastic %K and %D were 86.46% and 77.46%, respectively, and the average true range (ATR) was 0.58. With the 14-day stochastic at 89.98% and the average true range at 0.59, the RSI (14) stands at 60.30%. The stock has reached 0.31 on the 9-day MACD Oscillator while the 14-day reading was at 0.49.
Analyst Ratings
BofA Securities downgraded Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Day One Biopharmaceuticals Inc. (DAWN) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell DAWN, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 8 others rate it as a “buy”.
What is DAWN’s price target for the next 12 months?
Analysts predict a range of price targets between $9.00 and $54.00, with a median target of $40.00. Taking a look at these predictions, the average price target given by analysts for Day One Biopharmaceuticals Inc. (DAWN) stock is $38.78.
